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Abstract: The response to neoadjuvant chemoradiation therapy is an important prognostic factor for
locally advanced rectal cancer. Although the majority of the patients after neoadjuvant therapy are
referred to following surgery, the clinical data show that complete clinical or pathological response is
found in a significant proportion of the patients. Diagnostic accuracy of confirming the complete
response has a crucial role in further management of a rectal cancer patient. As the rate of clinical
complete response, unfortunately, is not always consistent with pathological complete response,
accurate diagnostic parameters and predictive markers of tumor response may help to guide more
personalized treatment strategies and identify potential candidates for nonoperative management
more safely. The management of complete response demands interdisciplinary collaboration includ-
ing oncologists, radiotherapists, radiologists, pathologists, endoscopists and surgeons, because the
absence of a multidisciplinary approach may compromise the oncological outcome. Prediction and
improvement of rectal cancer response to neoadjuvant therapy is still an active and challenging field
of further research. This literature review is summarizing the main, currently known clinical informa-
tion about the complete response that could be useful in case if encountering such condition in rectal
cancer patients after neoadjuvant chemoradiation therapy, using as a source PubMed publications
from 2010–2021 matching the search terms “rectal cancer”, “neoadjuvant therapy” and “response”.
Keywords: locally advanced rectal cancer; tumor response; predictive factors of complete response;
neoadjuvant therapy
1. Introduction
Rectal cancer represents approximately 35% of the total colorectal cancer incidence [1].
This is a heterogeneous type of cancer that attracts clinical attention due to the variety
of treatment options. Most of the patients with early rectal cancer can be managed by
surgery alone, however a significant proportion of patients present with a locally advanced
disease that demands neoadjuvant therapy (NAT) with a purpose to reduce the local tumor
burden and increase the safety and efficacy of further surgical treatment [2]. NAT involves
a variety of treatment options including radiotherapy and chemotherapy, used alone or in
combination [1].
Tumor response to NAT is an important prognostic factor for locally advanced rectal
cancer (LARC) [3]. Following NAT, a clinical complete response (cCR) can be obtained
in 10–40% of rectal cancer patients, however, it should be noted that the numbers of real
pathological complete responses (pCR) are on average two times less [1,2]. Patients with a
pCR to NAT have lower rates of local recurrence, improved survival as compared to patients
who don’t achieve pCR. The 5-year recurrence-free survival rates are 90.5%, 78.7% and
58.5% for patients with complete, intermediate and poor response [4]. Moreover, patients
with pCR after neoadjuvant chemoradiotherapy (nCRT) have improved distant metastatic
rates 7–10.5%, when compared to poor responders of NAT—26–31%, respectively [5,6].
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The possibility to predict patient’s response to nCRT would help to guide more
personalized treatment strategies [1]. This would allow a more precise selection of patients
who would benefit the most from nCRT, protect patients from potentially unnecessary
treatment, and allow identification of the best candidates for nonoperative management.
Unfortunately, at present, there are no certain preoperative predictive factors that could
determine the response to the NAT and could be implemented into clinical practice so
far [7].
2. Tumor Reaction to the NAT—Defining the Terms
Tumor reaction to the NAT is mainly described with the following terms–“downstaging”,
“downsizing”, “downshifting”, “regression” and “response” [8,9].
Tumor downstaging–characterizing the changes in tumor stage classification (0, I, II,
III and IV), describing the change from a higher stage group to a lower one (e.g., from stage
III to stage II).
“Tumor downshifting”–characterizing the changes in tumor extent (T1, T2, T3, T4),
lymph node involvement (N0, N1, N2) or presence of distant metastases (M0, M1), describ-
ing the change from a higher extent to a lower one (e.g., from T3 to T2).
“Tumor downsizing”–characterizing the decrease of the tumor size, but does not
always mean a simultaneous “downshifting” or “downstaging” (e.g., T3 tumor may reduce
in its size without reduction of the tumor extent).
“Tumor regression”–refers to the pathological ratio of residual viable tumor to scar
after NAT (chemotherapy, radiotherapy or combined) which reveals nothing about the
change in tumor size, nor about downstaging/shifting. Unfortunately, “tumor regression”
is often used to indicate all forms of tumor response to treatment [9].
“Tumor response”–may be classified as complete, incomplete or non-response. The
Response Evaluation Criteria in Solid Tumors (RECIST) guidelines were created in 2000
and later updated in 2009 (Table 1) [10].
Table 1. Revised RECIST guideline (version 1.1).
Grade Response Criteria
Complete response (CR) The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target)must have a reduction in short axis to <10 mm.
Partial response (PR) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baselinesum diameters.
Progressive disease (PD) At least 20% increase in the sum of diameters of target lesions, the appearance of one or more newlesions is also considered progression.
Stable disease (SD) Neither sufficient shrinkage to qualify for a partial response nor sufficient increase to qualify forprogressive disease.
A target lesion is defined as ≥10 mm measurable lesion present at baseline, up to a
maximum of five lesions total, representative of all involved organs, based on size. Non-
target lesions represent all other lesions (or sites of disease) including pathological lymph
nodes [10].
The revised RECIST guidelines are currently the closest standardized and accepted
response criteria available [3].
3. Complete Tumor Response after NAT
3.1. Clinical Complete Response (cCR)
In certain cases, tumors may completely respond to NAT. In general, cCR is defined
as the absence of clinically detectable residual primary tumor on clinical examination and
endoscopy at least 4 weeks after completion of NAT [1].
According to a recent systematic review by Dattani et al. (17 studies comprising
692 patients), the reported cCR rate was 22.4% [11]. Up to this, there have been several
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definitions of cCR described in studies focusing on the nonoperative management of rectal
cancer [12].
Definition of cCR by Brazilian group led by Habr-Gama who has the longest expe-
rience with this population and has attempted to standardize the classification of cCR
includes several clinical parameters: (1) absence of residual ulceration, (2) no mass or mu-
cosal irregularity, (3) absence of extra-rectal disease on imaging, (4) whitening of mucosa
and telangiectasia acceptable. Since a transient response is common, the authors defined
initial cCR occurring on first assessment >8 weeks after nCRT, and sustained cCR for
patients who maintain the response from 10 weeks until at least 12 months after nCRT [13].
Definition of cCR in the 2017 European Society for Medical Oncology (ESMO) guide-
lines is including several criteria:
Minimal criteria
1. the absence of any irregularities or a palpable tumor on digital rectal examination,
2. no visible lesion on endoscopy with the exception of a flat scar, telangiectasia, or
whitening of the mucosa;
Additional criteria
3. absence of any residual tumor in the primary site and draining lymph nodes on
imaging with magnetic resonance imaging (MRI) or endorectal ultrasound (ERUS),
4. negative biopsies from the scar,
5. an initially raised CEA level that returns to normal (<5 ng/mL) [2].
3.2. Pathological Complete Response (pCR)
Pathological complete response (pCR) is defined as an absence of viable tumor cells
after full pathologic examination of the resected specimen (pT0N0M0) [12]. Tumor re-
gression grade (TRG) is a method to stratify primary tumor response to NAT based on
a histopathological assessment of residual tumor cells and degree of tumor regression
and replacement. Various TRG classification systems are used—Mandard (1994), Dworak
(1997; modified Dworak—2003), Memorial Sloan-Kettering Cancer Center (MSKCC) classi-
fication (2008) and Ryan/American Joint Committee on Cancer (AJCC) 7th Edition (2010)
(Table 2) [1,13–16]. Mandard et al. introduced a TRG system for oesophagal carcinoma,
which has been applied in other digestive tract malignancies as well. In the Mandart
system TRG is classified into five grades, and CR is defined as TRG1—complete regression,
fibrosis extending through the different layers of the wall, no viable cancer cells. According
to Dworak et al. TRG is classified into four grades, and CR is defined as TRG4—no tumor
cells, only fibrotic mass or acellular mucin pools. Another classification offered by Ryan
et al. and is currently advised by the American joint committee on cancer (AJCC); in this
classification, TRG is classified into four grades and CR is defined as TRG0—no viable
cancer cells. MSKCC is offering classification of three groups, depending on the tumor
response rate; CR is defined as TRG1—100% tumor response.
Another 14 classification systems are described in the literature with different modi-
fications of TRG—Modified Mandard (Ryan) (2005), Werner and Hoffler (2000), Cologne
(2005), Bujko/Glynne Jones (2010), College of American Pathologists (2008), RCPath system
(1997), RCRG system (2002), Modified RCRG system (2009), Japanese classification (2012),
Ruo (2002), Junker and Muller (2003), Rodel (2005), Swellengrebel et al. (2014), Modified
Mandard TRGN by Dhadda et al. (2014) [17].
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Table 2. Most common TRG classification systems.
TRG Mandard Dworak Ryan/AJCC MSKCC
TRG 0 - no response CR, no viable cancer cells -
TRG 1
complete regression, no viable cancer cells,
fibrosis extending through the different
layers of the wall
minimal response (dominant tumor mass with
obvious fibrosis, vasculopathy); fibrosis <25% of
tumor mass
near-CR, single cells or rare small group of
cancer cells 100% tumor response
TRG 2 rare residual cancer cells scattered throughthe fibrosis
moderate response (dominant fibrotic changes with a
few easy-to-find tumor cells in groups); fibrosis
25–50% of tumor mass
partial response, residual cancer with evident
tumor regression but more than single cells or
rare small group of cancer cells
86–99% tumor response
TRG 3 increased number of residual cancer cells,fibrosis predominates
near CR (few microscopically difficult-to-find tumor
cells in fibrotic tissue with or without mucous
substance); fibrosis > 50% of tumor mass
poor or no response, extensive residual cancer
with no evident tumor regression ≤85% tumor response
TRG 4 residual cancer outgrowing fibrosis CR (no tumor cells, only fibrotic mass or acellularmucin pools) - -
TRG 5 absence of regressive changes - - -
TRG—tumor regression grade; AJCC—American Joint Committee on Cancer; MSKCC—Memorial Sloan-Kettering Cancer Center; CR—complete response.
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Irrespective of the grading system, assessment of pathological response is based on:
(1) tissues replacing tumor cells in areas where the tumor has regressed, (2) residual tumor
cells. These “replacement” tissues may be inflammatory or fibrotic; they may consist of
acellular mucin pools or calcifications and necrosis [14].
Analysis of the National Cancer Database in 2017 reported a pCR rate of 13% in overall
patient cohort 27,532 [16]. Unfortunately, cCR and pCR are not always consistent with
each other. In some studies, cCR was reported in up to 40% of the cases with NAT. After
surgery, it was observed that half of these resected specimens contained tumor cells at
histopathology examination [18,19]. Chari et al. found that even 22 of 43 (51%) patients
who underwent NAT for rectal cancer had a cCR, however, only 11 of those 22 patients had
a pCR [20]. Seong et al. reported a cCR rate of 23.8% in patients with primary unresectable
rectal cancer receiving NAT, however after resection—only 9.5% had a pCR [21]. Other
studies of complete clinical responders and pathologic complete responders (e.g., Issa et al.,
2012, Nyasavajjala et al., 2009, Nair et al., 2008, Hiotis et al., 2002) showed that in 33–81%
of cases there is a disconcordance between cCR and pCR [3]. Such a remarkable difference
is possibly related with a selected group of the patients (T2–T4 rectal cancer, initial node
positivity), applied therapy (type of radiation and/or chemotherapy), the used criteria
for cCR detection, the sensitivity of radiological investigations, the timing of the tumor
response evaluation, individual patient factors and interpretation of the specialist.
To distinguish these two groups of assessment in case of reached CR, it is offered to
apply an appropriate TNM staging, respectively–ycT0N0M0 in case of cCR and ypT0N0M0
in case of pCR [8].
4. Diagnostic Accuracy of CR
4.1. Reassessment/Response Assessment after NAT
The standard methods of clinical reassessment of patients after NAT are based on clin-
ical examinations that include digital rectal examination (DRE), proctoscopy or endoscopy
and re-imaging with MRI. These findings determine appropriate surgical strategy, the
type of planned operation and the possibility of applying a “watch and wait” (“W&W”)
strategy. It is recommended to re-evaluate the primary tumor and potential circumferential
resection margin (CRM) with MRI in LARC patients after NAT prior to resection to provide
clear surgical margins. Although, it must be considered that re-imaging after NAT may
both overestimate and underestimate (due to the poor discrimination between residual
tumor and radiation-induced fibrosis) pathological response and tumor downstaging [2].
Part of the concern in accurate determination of CR is that DRE, biopsy and post-NAT
MRI are unreliable for distinguishing fibrosis from small, residual islands of tumor tissue,
indicating a low positive predictive value [3]. The assessment methods of tumor response
after NAT and their predictive value are described further.
4.2. Digital Rectal Examination (DRE)
The objective examination is one of the most important procedures for the evaluation
of tumor response and DRE is irreplaceable in this. Quite often patients with tumor
regression have a reduction of symptoms. The basic criteria to consider a cCR during the
DRE include the absence of: (1) any palpable mass or irregularity, (2) ulceration, (3) stenosis.
The surface of the rectal wall has to be smooth and regular [22]. Although, a flat, small
ulcer with smooth edges and without signs of residual exulcerated or polypoid tissue may
be considered as a potential CR as well [23].
4.3. Proctoscopy/Endoscopy
Endoscopic evaluation of the originating area of the initial tumor is a persistent key
component of clinical assessment. Most of the applied “W&W” strategies have included
DRE and proctoscopy/endoscopy as part of the reassessment protocol. During the proce-
dure, it is important to seek for any superficial ulcer or irregularity missed during DRE.
Telangiectasia or a flat, white scar and loss of rectal wall elasticity are frequent endoscopic
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findings among patients with cCR. Possible signs of incomplete response include the
presence of: (1) any residual ulcer (deep or superficial, with or without necrotic center),
(2) significant stenosis of the lumen. Although flexible endoscopes may provide visual
documentation of clinical response, rigid proctoscopy may be an adequate extent for the
majority of patients. Overall, endoscopy is a helpful tool, but it is not sufficient on its own.
A weak point of endoscopy is that it provides information only about the luminal side of
rectum and nothing about the deeper layers and the mesorectum. As more remarkable
fibrotic changes during examination could be easily interpreted as a residual disease at
the site of the tumor, MRI can provide this additional information, that can be crucial for
further decision making [22–24].
4.4. Biopsy
In case of detected cCR in DRE and proctoscopy/endoscopy, additional biopsies
are not recommended. Even in the situation of incomplete clinical response, the biopsy
results should be interpreted with caution. The reported negative predictive values of these
biopsies among patients with significant response are low. Therefore, a negative biopsy in
the condition of incomplete clinical response does not exclude the presence of microscopic
residual cancer. The Sao Paulo group in 2012 did a retrospective comparative study to
find out the value of post-NAT biopsies and it was concluded that the sensitivity was 50%
and the negative predictive value—11%, which might be explained by the geographical
miss of the biopsy [25]. Several studies have tried to detect the presence of residual tumor
with post-NAT biopsies and the sensitivity of the examination was rated from 19.4–69.4%
(Perez et al., 2014–69.4%; Xiao et al., 2016–19.4%; Kuo et al., 2012–34.7%; Lopez-Lopez
et al., 2016–65.3%) [26]. Hayden et al. in 2012 introduced the concept of “tumor scatter”
defined as the (1) microscopic tumor cells present in the absence of a visible ulcer or (2)
presence of cancer cells outside of the visible ulcer. In this study, the residual tumor was
identified outside the visible ulcer or in the absence of an ulcer in 49% of cases and some of
the samples demonstrated the presence of the residual tumor cells up to 4 cm away from
the primary tumor bed [27].
One of the problems of downstaging/downshifting is the lack of homogeneity in
response options–there is significant heterogeneity in reaction to treatment even within one
tumor. This causes considerable difficulties in staging tumors with and without NAT: after
NAT, tumor can remain present in the outer layers of the rectal wall, while disappearing in
the inner layers, as it has been concluded in two independent studies [28,29].
Gosens et al. in 2007 raised an idea that there are at least two ways how rectal
cancer can respond to NAT: shrinkage or fragmentation. Shrinkage (reduction in the
direction of the mucosa) is the preferred way of response, often leading to downshifting of
T stage, allowing adequate monitoring with endoscopy or imaging and considering organ
preserving surgery or “W&W” strategy. Fragmentation (the destruction of the main tumor
mass and formation of small groups of tumor cells) is a condition more difficult to deal
with—the limited size of the tumor fragments is below the ability of resolution on imaging
and might lead to unradical surgical treatment or unfounded “W&W” strategy, resulting
in local recurrence [26].
Three recent studies (Perez et al., 2014; Hav et al., 2015; Fernandez-Acenero et al.,
2017–comprising 289 patients in total with LARC) showed that fragmentation was present
in 40% of cases, Smith et al. in 2014 in a study of 45 cT3 patients showed a fragmented
response in 80% of cases [26,30–33]. Fragmentation or scattering of tumor cells causes
also a clear inconsistency between macroscopy and microscopy. Tumor fragmentation is
associated with less downstaging, more frequent residual lymph node metastases, positive
resection margins in case of surgery and an overall poor outcome [26,27]. If fragmentation
is considered to be one of the response mechanisms, then this explains not only the limited
value of post-NAT biopsies but as well–higher recurrence rates in case of advanced tumors
during the “W&W” strategy [26,34].
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Another important fact to be noted–not all patients with clinically confirmed CR after
NAT have concurrent complete regression of lymph node metastases. The presence of
remaining a tumor in lymph nodes after a CR of the primary tumor is estimated to be found
in 7% of cases, demonstrating the diversity of therapy response [26,35]. This probability
seriously threatens the oncological safety in case of organ sparing surgery after NAT and
the application of the “W&W” strategy. The risk of lymph node positivity is dependent on
several factors related to tumor biology, including differentiation grade, histological type,
interaction with the microenvironment (i.e., tumor budding) and invasion of lymphatic
vessels [36].
4.5. Magnetic Resonance Imaging (MRI)
The accuracy of rectal cancer staging at MRI in post-NAT tumors is lower if compared
with a primary staging of rectal cancer at MRI [37].
To standardize the post-NAT imaging approach, MR-modified Mandard grading
system (mrTRG) has been used for the last decade to identify the post-therapy changes
(fibrosis/residual tumor) and define the responder groups depending on the qualitative
changes within the treated tumor [38]. Application of mrTRG can determine good and
poor responders. It does not correlate directly with histopathological TRG, and there is a
discrepancy with RECIST tumor measurements [2].
According to the mrTRG grading system patients are categorized in 5 groups: TRG1—
complete radiologic response, TRG2—good response, TRG3—moderate response, TRG4—
slight response, TRG5—no response [38,39].
Scoring systems established by the European Society of Gastrointestinal and Ab-
dominal Radiology (ESGAR) and the Magnetic Resonance Imaging and Rectal Cancer
European Equivalence Study (MERCURY) study group are mostly similar but there are
some differences in their definitions of good responders (Table 3) [40].
A recent analysis by Seo et al. in 2019 claimed that mrTRG is ten times more likely to
identify patients with pCR if compared with isolated clinical assessment, especially in case
of residual mucosal abnormality [41].
An analysis of 33 studies reported that on post-NAT restaging with MRI using stan-
dard T2 weighted sequences the overall sensitivity and specificity was 50% and 91%. The
relatively low sensitivity is related to the fact that conventional MRI cannot differentiate
between fibrosis and a tumor.
Some studies show that sensitivity of the examination can be notably improved after
adding diffusion-weighted imaging (DWI) but without any particular effect on speci-
ficity [42]. The apparent diffusion coefficient (ADC) measured via DWI-MRI is a typical
radiological marker of the nCRT response of rectal cancer [43]. As diffusion properties of
water molecules may differ in regions of high cellularity (often observed within tumor
tissues), tissue necrosis or fibrosis, it may be used as a helpful tool to evaluate tumor
response to nCRT [44]. ADC quantifies such restriction to diffusion of water molecules
(observed as high signal intensity in the region of the previous tumor) and it has been
associated with CR [45].
Lambregts et al. in 2011 studied total 120 patients with LARC who underwent CRT
and post-NAT evaluation by standard T2 weighted MRI and DWI for identification of
complete responders. The sensitivity ranged from 0–40% on standard MRI vs. 52–64% after
the addition of DWI. It was concluded that DWI-MRI could significantly improve not only
the sensitivity for identification of complete responders but also the specificity which was
found to be greater than 90%, subsequently, the risk for underestimation of the residual
tumor could be reduced to <10% [43]. Although, Maastrich group work in 2015 showed
that radiological assessment with additional DWI missed 15% of patients with pCR [23].
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Table 3. Evaluation systems of rectal cancer response in post-NAT MRI.
Grade Response mrTRG (2012) MERCURY (2012) MERCURY (2016) ESGAR (2016)
mrTRG 1 Complete
No evidence of treated tumor. Thin fibrosis, low-density
signal on T2-weighted images with no evidence of
intermediate signal intensity at the site of the treated disease.
No evidence of tumor signal
intensity or fibrosis only
Linear/crescentic 1–2 mm





Dense fibrosis (>75%); no obvious residual tumor, signifying
minimal residual disease, or no tumor. Dense fibrosis with no




No obvious residual tumor,
signifying minimal residual




>50% fibrosis or mucin and visible intermediate signal
intensity. Predominating low signal fibrosis with







Residual mass (and/or focal
high signal intensity on
diffusion-weighted imaging)
mrTRG 4 Slight
little areas of fibrosis or mucin, but mostly tumor.
Predominating intermediate T2-weighted signal with
minimal or no fibrosis present.
Little areas of fibrosis/mucin,
but mostly tumor
Little areas of fibrosis/mucin,
but mostly tumor
mrTRG 5 No response
Intermediate signal intensity; same appearance as that of the
original tumor. Predominating intermediate T2-weighted
signal with minimal or no fibrosis present.
Intermediate signal intensity,
same appearances as original
tumor/tumor regrowth
Intermediate signal intensity,
same appearances as original
tumor/tumor regrowth
mrTRG—MR-modified Mandard grading system; MERCURY—Magnetic Resonance Imaging and Rectal Cancer European Equivalence Study; ESGAR—European Society of Gastrointestinal and Abdominal
Radiology
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Another commonly investigated functional MRI technique is dynamic contrast-enhanced
(DCE) or “perfusion” MRI. DCE-MRI can obtain quantitative parameters related to mi-
crovascularity and tissue perfusion by measuring the inflow of intravenously injected
contrast agents and the leakage of contrast into the extracellular space, which have shown
significant correlations with tumor response. Although DCE-MRI is already routinely
applied in breast and prostate cancer imaging, in case of rectal cancer it has been applied
only under research conditions [45].
Less frequently studied techniques include MR spectroscopy, blood oxygenation level-
dependent (BOLD) MR and magnetization transfer (MT) imaging. Improved methods
of DWI acquisition such as diffusion kurtosis imaging (DKI) and intravoxel incoherent
motion (IVIM) imaging have also been described [45].
4.6. Computed Tomography (CT)
CT is not applied for evaluation of the local response of rectal cancer after nCRT due
to its relatively lower sensitivity and specificity if compared with MRI. Due to the poor
soft-tissue contrast, the accuracy of standard CT scan in evaluation and prediction of pCR,
has been estimated at less than 50% [46].
CT is used only for pre-treatment radiological TNM staging and routine restaging of
the chest and abdomen is not recommended even after nCRT. Only patients with initially
more advanced cancers (cT4, cN2), the presence of extramural venous invasion (EMVI)
and threatened CRM should be re-staged within 3 months from primary staging to exclude
progressive metastatic disease [2].
4.7. Positron Emission Tomography/Computed Tomography (PET/CT)
Radiologic investigations that include additional metabolic information in comparison
with standard radiologic imaging are expected to improve the overall accuracy of complete
tumor response identification. PET-CT imaging has been evaluated for the prediction of
response to NAT, although the role of this investigation has not been clearly defined yet [3].
The application of molecular imaging may add information to standard struc-
tural/anatomical features and provide better differentiation of fibrosis and residual tu-
mor. The use of Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) allows to evaluate tissue
metabolism (standardized uptake values–SUV) of essential regions, and fused images of
PET and CT may point out residual cancer tissue [47].
For the detection of residual cancer tissue, PET-CT findings present sensitivity of 93%
and specificity of 53% and overall accuracy of 85% [3]. The accuracy of PET-CT in the
prediction of cCR reaches 96% if it is combined with clinical evaluation [48].
Considering the fact that a metabolic CR is not equivalent to pCR in all cases, several
aspects are being assessed to increase the value of PET-CT (e.g., the metabolic tumor
volume; the total lesion glycolysis (TLG) and change of its percentage; a reduction in the
maximal SUV by applying variable interval periods) [7,48].
A study by Perez et al. in 2012 has recommended the combination of volumetric
reduction in tumors and SUV variation to predict CR to NAT. Application of individual
technical calibration for evaluation of metabolic tumor volumes and variation in TLG
(determined by mean SUV values and metabolic tumor volume) was admitted to be
the best predictor of response to NAT when used at baseline and 12 weeks from NAT
completion [49].
Metser et al. assessed the correlation between radiomic features and pCR by using
machine learning algorithms and found that the systematizer trained on pre-treatment
PET-CT had an accuracy of 92.8% in predicting pCR to NAT in patients with LARC [50,51].
4.8. Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)
Although there is a limited number of clinical studies regarding the role of PET/MRI
in post-NAT rectal cancer evaluation, still it has been proven to be at least equivalent to
PET/CT and to standalone MRI due to its accuracy in T and N staging [52].
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The systematic review of Crimì et al. in 2021 revealed that the reported sensitivity of
T staging in [18F] FDG PET/MRI was in the range of 94–100%, specificity 73–94%, and
accuracy 92–100%. The reported sensitivity, specificity, and accuracy for N staging were
90–93%, 92–94%, and 42–92% accordingly [53].
Several studies confirm that PET/MRI may be used for rectal cancer restaging after
NAT and to select patients for rectum-sparing surgical approaches with potentially higher
accuracy if compared with PET/CT and MRI alone [54–58].
4.9. Endorectal Ultrasound (ERUS)
ERUS, although proven to be a valuable method for the initial staging of rectal cancer,
is unfortunately not the best choice in tumor reassessment after treatment [46]. The ability
of accurate evaluation of tumor response to NAT with ERUS is restricted by the effects
of the chemoradiation: tumor fibrosis, necrosis and peritumoral inflammation caused by
therapy can remarkably compromise the preciseness of staging. All these reactions may
look sonographically indistinguishable from residual tumor and may reduce the ability
to differentiate the five layers of the rectal wall and result in over-staging. In general, it
seems that ERUS has a particular role in restaging rectal cancer after NAT, but still, some
specific changes in the rectal wall and surrounding structures have to be taken into account
to avoid false staging [3].
5. Therapy-Related Predictive Factors of CR
5.1. Modalities of Neoadjuvant Radiation Therapy
5.1.1. External-Beam Radiation Therapy (EBRT)
EBRT is the primary radiation technique used for NAT. It delivers radiotherapy (RT)
to the rectal wall harbouring the primary tumor as well as to the complete mesorectum to
treat tumor deposits in it [9].
Two different schedules of preoperative RT are standards of care–short-course preoper-
ative radiation therapy (SCPRT) and long-course preoperative radiation therapy (LCPRT):
1. SCPRT also known as the 5 × 5 Gray (Gy) regimen, offers 5 daily doses of 5 Gy (total
of 25 Gy) and is usually followed by radical resection within one week of completing
RT (<10 days from the first radiation fraction). SCPRT with delayed surgery is also
a useful alternative to conventional SCPRT with immediate surgery offering similar
oncological outcomes and lower postoperative complications [3];
2. LCPRT regimens deliver daily doses of RT in significantly smaller fractions (about
1.8–2 Gy) over a longer period of 25 days to 28 days. The total RT dose delivered by
this regimen is 45 Gy to 54 Gy and seems to be biologically equivalent to the 25 Gy
short-course regimen [59].
It is not possible to give a rigid definition of which T and N sub-stages require SCPRT
or nCRT [3]. In deciding whether to use SCRT vs. long-course nCRT, multidisciplinary
considerations must be made, including the possibility of long-term toxicity and the need
for tumor downstaging prior to surgery [1].
Two randomized comparative studies of SCPRT and LCPRT have been performed
so far. The first was a Polish study published in 2006, which compared 155 patients who
underwent SCPRT and 157 who underwent LCPRT [60]. The pCR rate was 0.7% for the
SCPRT group and 16.1% for the LCPRT group. There was no difference in the incidence of
postoperative complications or late effects, and no significant difference in overall survival
(OS), relapse-free survival, or local recurrence rates between the two groups. Another
randomized comparative study of SCPRT and LCPRT in 163 patients was carried out in
Australia in 2012 [61]. Alike to the Polish study, this research also found that the pCR
rate was only 1% in the SCPRT group, compared with 15% in the LCPRT group, and
there were no differences in the incidences of postoperative complications or late effects,
or the OS or local recurrence rates. The results of these two comparative studies were
very similar, suggesting that SCPRT may have potential as a treatment that provides local
control equivalent to that achieved by LCPRT without increasing postoperative or late
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complications [62]. Considering the influence of time on the development of CR to therapy,
it has been suggested that SCPRT followed by delayed assessment of response may result
in similar rates of CR to the observed after LCPRT [8].
For the treatment of LARC, a radiation dose of 45–54 Gy is recommended in the
National Comprehensive Cancer Network (NCCN) and European Society for Medical
Oncology (ESMO) consensus guideline. Nevertheless, Burbach et al. in 2014 found that
dose escalation above 60 Gy for LARC results in high pCR rates and acceptable early
toxicity [63]. In addition, Appelt et al. in 2013 demonstrated a significant dose-response
relationship for tumor regression after preoperative CRT for LARC for dose levels in the
range of 50.4–70 Gy [64]. These findings suggest that over 50 Gy of RT may be clinically
relevant with acceptable toxicity; however, no major prospective trials exploring doses
over 50 Gy have been performed yet. Additional studies are needed to confirm the safety
and efficacy of dose escalation [62].
5.1.2. High Dose Endorectal Brachytherapy (HDRBT)
HDRBT offers the advantage of the direct delivery of higher doses of RT to the mural
rectal tumor, minimizing skin and sphincter exposure [62]. During preoperative HDRBT, 26
Gy is delivered in four daily applications of 6.5 Gy, covering the clinical target volume [65].
The HDRBT effect is limited to a 2-cm radius from the primary tumor, so it provides limited
treatment of the mesorectal lymph nodes, blood and lymphatic vessels [62]. In a recent
systematic review of 22 studies by Buckley et al. in 2017, it was concluded that the pCR rate
following preoperative HDREBT with CRT ranged between 18% and 31% (weighted mean
rate—22.2%). After preoperative HDREBT alone, the pCR rate ranged between 10.4% and
27% (weighted mean rate—23.8%). Preoperative HDREBT either alone or in combination
with nCRT may result in a better pCR [66].
5.1.3. Contact X-ray Brachytherapy (Papillon)
Contact RT was initially described by Papillon et al. (introduced in 1974) as another
method for the direct delivery of RT to the rectal wall using a rigid proctoscope and a
specially designed RT machine [62]. Contact X-ray brachytherapy (CXB) uses low-energy
(50 keV) X-rays which are deposited mainly on the surface of the tumor and penetrate
only a few millimetres of tissue beneath the tumor. Therefore, exophytic tumors are more
suitable for this procedure than deeply infiltrative tumors [62,67]. X-rays are applied
straight to the tumor under direct vision, minimizing the chance of a geographic miss. The
dose falls off rapidly–the 100% dose is prescribed at the surface and the dose falls to 60%
at 5 mm depth [68]. CXB treats only a small volume, usually <5 cm3 of tissue, compared
with EBRT which treats much larger volumes of tissue, of about 1000–1500 cm3. Therefore,
very high doses of radiation (~30 Gy, but with a biological dose equivalent to 100 Gy)
can be safely delivered at each treatment fraction with very little collateral damage to the
normal tissues around the tumor [62,67]. The treatment is given three times (30 Gy × 3)
every two weeks. This regimen allows the normal tissues to recover during the 2-week
break [68,69]. Like HDRBT, there is minimal toxicity but also minimal, if any, activity
within the mesorectum. This treatment strategy has been suggested for the management of
early tumors by RT alone as a form of local therapy or as a neoadjuvant approach followed
by resection [62].
In a single centre experience where all patients received combined CXB and EBCRT–
an initial cCR was seen in 144 (72%) of 200 patients following CXB [67]. The benefits of
CXB were confirmed in Phase III randomised controlled trial in 2004–cCR was greatly
increased in patients who received EBRT and CXB treatment compared to EBRT alone (24%
vs. 2%) [70].
5.2. Modalities of Neoadjuvant Chemoradiation Therapy (nCRT)
Concurrent chemotherapy (ChT) during neoadjuvant RT has the added benefit of
improved tumor downstaging and local control compared with RT alone [71]. In multiple
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phase II trials of LARC patients treated with preoperative RT alone, the pCR rates were
notably lower (4–13%) if compared to the studies in which patients were treated with
combined CRT (9–31%). Several randomized trials have demonstrated the benefits of
adding concurrent chemotherapy to SCPRT and LCPRT by increasing local sensitization
and systemic control of the disease [2,72–75].
In the ESMO and NCCN consensus guideline, 5-FU based chemosensitizers are
recommended with conventional RT for the treatment of LARC to increase sensitivity to
radiation [62,72]. According to ESMO guidelines, continuous intravenous infusions of 5-
fluorouracil (5-FU) or oral capecitabine during CRT are recommended [2]. The equivalence
of infusional 5-FU and capecitabine (an oral agent converted in tissues to 5-FU) has been
established by the NSABP R-04 randomized controlled trial concerning rates of pCR,
surgical downstaging, and sphincter preservation [2,73].
Several studies have investigated the usefulness of additional drugs with 5-FU-based
chemosensitizers to improve the response rate. The largest number of prospective phase
III randomized studies have tested regimens that incorporate oxaliplatin (ACCORD,
CAO/ARO-04, STAR-01, FOWARC and NSABP R04 trials), showing controversial ef-
fects on the difference in pCR rates (no difference in pCR in STAR-01, NSABP R-04 and
ACCORD 12/0405-Prodige 2 trial; higher rates of pCR in the group receiving oxaliplatin
17% vs. 13% in CAO/ARO/AIO-04 trial) [2,72]. Although most of these trials found
that there was minimal or no difference in response rate between the two groups, acute
toxicity and adverse events were significantly more common in patients who also received
oxaliplatin [1,62]. Hence, the decision about adding oxaliplatin should be risk-balanced,
taking into account the predicted toxicity for a particular patient [3].
Another promising radiosensitizer CPT-11 (camptothecin-11, irinotecan) has been
evaluated in several published phase II trials, noting the usefulness of adding CPT-11 to
CRT and reporting a pCR rate of 25–34% (Mehta et al., 2003; Choi et al., 2008). Although on
the contrary some studies (Gollins et al., 2011; Mohiuddin et al., 2013) revealed that there
was no significant difference between the treatment in terms of pCR or downstaging, an
increased rate of acute toxicity was reported in the irinotecan group. Further studies are
needed to confirm the usefulness of CPT-11 as a radiosensitizer [72,76].
Epidermal growth factor receptor (EGFR) inhibitors like panitumumab and cetuximab
are already approved for the treatment of RAS wild-type metastatic colorectal cancer, but
their role in LARC remains unclear. The results of adding cetuximab to 5-FU–based CRT
regimens were disappointing–a pooled analysis of available studies indicate a pCR rate
of less than 10% for combination therapy compared with 15% to 30% for standard 5-FU
regimens and unacceptable toxicity as well. Panitumumab—only a few phase II trials have
been published and the authors concluded that the addition of panitumumab to nCRT did
not achieve the primary endpoint of expected pCR with additionally high toxicity [72,76].
Consequently, there is currently no role for the addition of EGFR-targeted therapy as a
radiosensitizer in the treatment of LARC [76].
Anti-angiogenesis therapy with bevacizumab and sorafenib have not been approved
themselves yet as well. Bevacizumab in combination with standard CRT has shown
potential for rectal cancer although was not giving the expected increase in pCR. Sorafenib
was giving encouraging results but still limited in small cohorts and phase I studies [76].
Poly (ADP-ribose) polymerase inhibitors (PARPs) like veliparib plus capecitabine-
based CRT are demonstrating a pCR rate of 28%, although this class of potential radiosen-
sitizer remains an area of interest and future studies are needed to clarify its role in rectal
cancer [76].
With a clear focus of research on optimizing NAT, several novel modalities have
been investigated–immunotherapy agents, cyclo-oxygenase 2 inhibitors, prostaglandin
E2 receptor inhibitors, Ad3/Ad11p chimeric adenoviruses and nanoparticles etc. Despite
extensive research and promising preclinical studies, a definite further agent in addition to
fluoropyrimidines that consistently improves response rate has yet to be found [76].
Medicina 2021, 57, 1044 13 of 29
Since combining drugs during nCRT regimens has failed to improve pCR rates, differ-
ent schedules for the delivery of ChT in the neoadjuvant setting have been investigated [9].
The twofold rationale (known as well as “total neoadjuvant therapy”) for giving neoad-
juvant ChT sequentially, either before or after nCRT, followed by surgery, was derived to
improve the response of the primary tumor and to reduce the distant metastasis rate [76].
Additional chemotherapy before the start of standard nCRT is known as “induction
chemotherapy”, however, no randomized comparative clinical trial has demonstrated that
induction chemotherapy significantly improved the pCR rate, and the increased toxicity
and even mortality associated with this treatment strategy has limited its widespread
adoption and data acquisition till 2020 when new trials appeared [9,62].
Another delivery modification of ChT, known as “consolidation chemotherapy”, that
includes standard nCRT followed by ChT during the “resting period” between nCRT and
surgery, has yielded more promising results. High CR rates of up to 65% have been reported
compared with historical controls of nearly 30% with more conventional nCRT regimens [9].
This regimen is attracting attention as a method of making use of the period between nCRT
and surgery. As a longer waiting period after nCRT increases the pCR rate, there has been
a tendency to extend this period in recent years. In some cases, it may exceed 2 months,
and the goal of consolidation chemotherapy is to improve the pCR rate by the addition
of FOLFOX or another chemotherapy regimen during this long waiting period [62]. The
TIMING (Timing of Rectal Cancer Response to Chemoradiation) trial was a multicenter
prospective phase II study examing the effect of adding 0, 2, 4 or 6 cycles of consolidation
FOLFOX after nCRT in stage II-III LARC patients–pCR rates were significantly increased
from 18% in the standard therapy group to 38% in the group receiving 6 cycles of FOLFOX
with no difference in adverse events [77].
5.3. Neoadjuvant ChT
Neoadjuvant ChT alone using a fluoropyrimidine and oxaliplatin or combined with
targeted agents has been proposed instead of nCRT in cT3 tumors, not threatening the
CRM and cT4 tumors in the mid- and upper- rectum, to promptly treat potential mi-
crometastases and individualising treatment options [3]. The FOWARC phase III study
randomized 495 patients with LARC to either standard nCRT using concurrent 5-FU, nCRT
with concurrent 5-FU and oxaliplatin, and FOLFOX chemotherapy alone. Although tu-
mor downstaging was comparable between the standard nCRT and chemotherapy-alone
arms (37.1% and 35.5%), the pCR rate was inferior with chemotherapy alone (14% vs.
6.6%) [78]. It was reported recently that there was no difference in disease-free survival
(DFS) or OS between the three arms [79]. At present, there is more evidence to support the
replacement of nCRT with chemotherapy using DFS as the primary endpoint, than for a
cCR/organ preservation endpoint [76]. Hence, at this moment neoadjuvant ChT alone is
not recommended for the treatment of localised, non-metastatic disease [3].
5.4. Interval to the Surgery
The optimal timing of surgical resection of LARC after nCRT or SCPRT remains contro-
versial and is studied in trials. The ideal interval requires a balance between sufficient time
after the RT for the maximal effects to be fully expressed (but before tumor repopulation)
and the acute tissue reaction so that surgery can be carried out safely [3].
Tumor response to nCRT is time-dependant, sometimes taking months to achieve
maximal tumor regression. Traditionally, the recommended interval between completion
of NAT to surgery is 6–8 weeks–a timeframe that promotes tissue response and recovery
from radiation and prevents the development of radiation-associated tissue fibrosis [2].
In a practice, there is a wide variation in the timing of surgery (4–12 weeks) due to
recovery from treatment, patient/surgeon choice and waiting list issues [3].
There is an ongoing discussion on the best interval between treatment ending and
response assessment. In the context of the “W&W” strategy, the aim is finding the perfect
balance between the greatest tumor regression, therefore increasing the patient’s chance of
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being eligible for a “W&W” approach, while providing a safe and successful surgery, if
surgery is inevitable. Several retrospective studies have suggested a higher rate of pCR
when delaying surgery after nCRT [25].
In the case of SCPRT in resectable cancers, where downstaging is not required, “imme-
diate” surgery is recommended to take place within 7 days from the end of NAT [3]. The
Dutch trial (Marijnen et al., 2001) confirmed that preoperative SCRT also does not signifi-
cantly downstage the tumor if the radiation-to-surgery interval is less than 10 days [80]. In
case of SCPRT followed by “immediate” surgery (within 1–2 weeks) and “delayed” surgery
(5–13 weeks)–earlier yp histopathologic stages and tumor categories, higher rates of pCR
(11.8% vs. 1.7%) and higher rates of Dworak TRG4 (10.1% vs. 1.7%) were observed in case
of “delayed” surgery [81].
If organ preservation is the goal–LCPRT (or SCPRT in non-fit patients) with a delay
of 6 weeks until the first evaluation of tumor response is recommended. If there is no
good response, surgery should be performed within 2 weeks. In case if cCR or near-cCR is
achieved, restaging should be carried out after another 6 weeks, at which time the decision
could be made whether or not to implement the “W&W” strategy [75]. Currently, the
interval from the end of nCRT to surgery is based on the Lyon R 90-01 trial. This trial
demonstrated that preoperative RT increased the rate of a pCR or near pCR from 10.3%
at 2-week intervals to 26% at 6- to 8-week intervals. Thus far, the optimal interval is
considered to be 6–8 weeks. The rationale for this interval is that it is expected to increase
the pCR rate and reduce postoperative complications [82–84].
As to date, there is no final consensus regarding the interval between the end of nCRT
and time to surgery, due to the promising results of clinical response in case of extension of
the waiting period between NAT and surgery, and there is an observable trend in clinical
trials to make careful delay of the surgery.
Because radiation-induced necrosis requires time to develop, a prolonged interval
between radiation and surgery potentially increases pCR occurrence. In the study of
Kleiman et al. in 2015, it was concluded that a radiation-surgery interval >8 weeks was
associated with high pCR rates [85]. A meta-analysis incorporating 3584 patients by Petrelli
et al. in 2016 reported an increase in pCR rates from 13.5% for an interval of 6–8 weeks to
19.5% for intervals longer than 8 weeks [86]. The observation that the post-nCRT lymph
node positivity rate of 12% declines to less than 5% after an 8-week waiting period also
supports the value of a longer waiting time [9].
However, the GRECCAR-6 trial revealed no significant difference between long
(11 weeks) and short intervals (7 weeks) concerning pCR occurrence, although greater
complications and difficulties in surgery were observed for participants with an 11-week
interval [87].
Controversial results were also observed by Sun et al. who assessed the US National
Cancer Database (NCDB) to answer the question of optimal timing. The overview included
11,760 patients with stage II-III rectal adenocarcinoma, treated between 2006 and 2012,
who received nCRT followed by surgery. The authors found out that tumor downstaging
increased during the waiting period, but when passed 56 days (8 weeks), there was no
added benefit of delaying the surgery [88].
On the opposite, a retrospective review of more than 17,000 rectal cancer patients
from the National Cancer Database found the optimal waiting period was 10–11 weeks,
with a 27% greater odds of pCR for this interval compared to an interval of surgery of
6–8 weeks [2].
A comprehensive meta-analysis and systematic review was conducted by Donlin
et al. in 2018—13 studies involving 19,652 patients were included. The meta-analysis
demonstrated that pCR was significantly increased in patients with LARC and a waiting
interval of ≥8 weeks between preoperative nCRT and surgery compared to a waiting
interval <8 weeks or waiting interval of >8 weeks compared to ≤8 weeks. There were
no significant differences in operative time, OS, DFS, the incidence of local recurrence,
postoperative complications or sphincter preserving surgery. This study revealed that
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performing surgery after a waiting interval of 8 weeks after the end of preoperative
nCRT is safe and efficacious for patients with LARC, significantly improving pCR without
increasing operative time or incidence of postoperative complications [89].
In a British study by Evans et al. in. 2016, including patients considered to have a
locally advanced disease–tumor downstaging recorded with MRI was higher in the group
of patients had waited for 12 weeks rather than 6 weeks (58% vs. 43%), as were the rates of
pCRs (20% vs. 9%) [90].
A further multicentre study by Figueiredo et al. in 2018 investigated outcomes for
rectal cancer patients treated with surgery over 12 weeks after completing NAT (n = 76).
Histopathological analysis of the resected surgical specimens demonstrated a pCR rate of
8.3% for those undergoing surgery within 12 weeks and 15.8% for those with extended
interval to the surgery. There were no significant differences found regarding morbidity
and mortality in either group [91].
In a study by Sloothak et al. in 2013, the pCR rate was significantly higher in patients
with an interval of 15–16 weeks between CRT and surgery (18%) compared with the other
time intervals (10.3% for less than 13 weeks, 13.1% for 13–14 weeks and 11.8% for more
than 16 weeks respectively). These data suggested that delaying surgery until the 15th or
16th week after the start of nCRT (week 10 and 11 after a 5-week nCRT regimen) results in
the highest chance of a pCR in patients with rectal cancer [92].
Another study by Garcia-Aguilar et al. in 2015 included patients with nCRT regimens
and progressively longer interval periods before surgery. Although this was not a random-
ized study, patients in different groups were comparable. It was concluded that patients
undergoing surgery after 12 weeks developed similar postoperative complication rates
when compared with the standard 6-week interval. The study then kept on recruiting
patients for progressively longer intervals: 6, 12, 18, and 24 weeks between nCRT and
surgery. Even though additional systemic chemotherapy was offered to patients undergo-
ing surgery after longer interval periods, delaying surgical resection to 20 weeks resulted
in significantly higher pCR rates, with no negative impact on postoperative morbidity [93].
6. Host Related Predictive Factors of CR
6.1. Clinical Parameters
There are many characteristics of the patient that could potentially affect the outcome
of the treatment. Examples include the presence of chronic disorders such as inflammatory
bowel disease or diabetes and active smoking [25]. No-smoking history is found to be
a clinical predictor for pCR in rectal cancer patients treated with long course nCRT [94].
Medication can be an important influencing factor, e.g., immunosuppressor agents like
cyclosporin, tacrolimus or even simple corticosteroids. Currently, there is not much data
about the interaction of medication and response to the treatment, but studies have found
that the use of statins increases tumor regression with CRT [25]. As well–young age is a
reported predictive factor of lower pCR rate following NAT [95].
6.2. Genetic Predisposition
Several specific genomic alterations associated with treatment response have been
identified. Nine single-nucleotide polymorphisms (SNPs) were found to be associated with
a better response to neoadjuvant CRT. For example, coronin 2A (CORO2A) rs1985859 was
associated with a positive histopathologic response to CRT. Patients that are homozygous
C/C genotype in MTHFR gene (rs1801133) were also found to be more predisposed to
respond to CRT. Likewise, SNPs in the genes associated with miRNA processing (rs744910,
rs745103 and rs1722821 for SMAD3; rs10719 for DROSHA; rs6088619 for TRBP) have also
been found to be significantly associated with nCRT response in LARC patients [2].
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7. Tumor Related Predictive Factors of CR
7.1. Clinical Parameters
Tumor size (≥3 cm), volume, tumor circumferential extent >60%, higher pre-treatment
T stage is associated with highly aggressive tumor behaviour, indicating lower sensitivity
to nCRT and lower rates of downstaging [96–98]. Tumor distance from the anal verge is
strongly related to the clinical response as well. A retrospective analysis of Das P. et al. in
2007 (n = 562) revealed that the distance from the anal verge >5 cm was associated with
significantly lower downstaging rates [96]. In a study by Bitterman et al. in 2015 (n = 138),
the tumor distance ≥3 cm from the anal verge was found to be an independent predictor of
lower CR rates [97]. In a prospective study of Patel et al. in 2016 (n = 827) where pCR was
reached by 20% of the patients, it was found that pCR rates were 11% for tumors <4 cm,
24% for tumors 4–6 cm, 30% for tumors at 6–8 cm, 17% for tumors 8–10 cm, and 14% for
tumors >10 cm from the anal verge. Patients with low tumors (<4 cm) and higher tumors
(>8 cm), were less likely to have a pCR [99].
Clinically node-positive disease at the moment of diagnosis is an independent pre-
dictor of clinical response and is associated with decreased chance of achieving CR. It is
possible that clinical node positivity may be a marker for a more aggressive disease that is
less sensitive to local therapy [97,100]. pCR rates in clinically node-negative diseases are
found to be three times higher than in node-positive diseases [101].
7.2. Morphological and Immunohistochemical Parameters
The presence of mucinous histology, poor tumor differentiation, macroscopic ulcera-
tion is related to decreased response rates [102–104]. Additional morphological parameters
in untreated patients that play the role in overall prognosis and in the possibility to reach
CR are–tumor budding and tumor-stroma ratio (TSR). The role of tumor budding (single
tumor cells and small groups of tumor cells) is associated with a lack of response to NAT
and a poor outcome in general as tumor buds are considered to be a feature of epithelial-
mesenchymal transition and it is associated with the mesenchymal subtype. The role of
TSR as a prognostic factor–the presence of extensive stroma between groups of tumor
cells is associated with a poor outcome [26]. The relation between mucin pool formation
also described as a colloid response, and NAT has been known for a long time as well. In
patients with a pCR, approximately 27% of patients present with acellular mucin pool, but
it is found that in pCR patients it does not affect prognosis [34].
In a review of Dayde et al. in 2017 extensive overview of tumor biomarkers was carried
out. Expression of different proteins has been associated with response to nCRT, including
vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), p21,
B-cell CLL/lymphoma 2 (Bcl2), BCL2-associated X protein (Bax), a marker of prolifera-
tion Ki-67 (ki-67), p53, hypoxia-inducible factor 1-α (HIF1-α), cyclooxygenase-2 (COX-
2), E-cadherin, thymidylate synthase, matrix metalloproteinase-9 (MMP-9) and matrix
metalloproteinase-2 (MMP-2). Protein biomarkers in tissues have been widely investigated
and newly identified protein biomarkers are listed: ataxia telangiectasia mutated (ATM),
meiotic recombination 11 homolog A (MRE11), X-ray repair cross-complementing protein
2 (XRCC2), cell cycle (polo-like kinase 1 (Plk1), PCNA-associated factor 15 (Paf15), c-MYC
and proliferating cell nuclear antigen (PCNA), vaccinia-related kinase-1 and -2 (VRK1 and
VRK2), focal adhesion kinase (FAK), golgi phosphoprotein 3 (GOLPH3), nuclear factor-κB
(NF-κB), fibroblast growth factor receptor 4 (FGFR4), apoptotic protease-activating factor
1 (APAF-1) and COX2, survivin, Plectin-1 (PLEC1), Beclin 1 and desmoglein 3 (DSG3),
transgelin (TAGLN), vascular non-inflammatory molecule 1 (VNN1), transketolase (TKT)
and hydroxyacyl-CoA dehydrogenase (HADHA), 17-β-hydroxysteroid dehydrogenase
type 2 (HSD17B2), 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMGCS2) [105].
A study by Linders D et al. in 2021 presented tumor-targeted near-infrared (NIR)
fluorescence imaging as a potential tool to improve response evaluation. The method
allows real-time optical imaging by selectively highlighting cells that express certain
molecular targets. To investigate the applicability of these targets, analysis of protein
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expression by immunohistochemistry in the tissue of rectal cancer patients with a pCR was
performed. Promising targets in rectal cancer included carcinoembryonic antigen-related
cell adhesion molecule 5 (CEACAM5, referred to CEA), epithelial cell adhesion molecule
(EpCAM), urokinase-type plasminogen activator receptor (uPAR) and αvβ6 integrin. The
immunohistochemical evaluation showed that EpCAM and CEA could be suitable targets
for response evaluation after NAT, since the expression of these targets in the primary
tumor bed was low compared with the diagnostic biopsy and adjacent pre-existent rectal
mucosa in more than 90% of patients with a pCR [106].
Although several molecular biomarkers have been proposed as predictive of response
to nCRT, none of these has reached the regular clinical application yet [107].
The comparison of the tumor immune microenvironment may also offer insight into
the predicted response to NAT. Tumor-infiltrating lymphocytes (TILs)–low stromal Foxp3+
cell density is significantly associated with a good response to neoadjuvant CRT. Low PD-
L1 expression both before and after nCRT is a negative prognostic marker, while another
study demonstrated that high PD-L1 expression after nCRT was associated with vascular
invasion, tumor recurrence and poor recurrence-free and OS [2].
A very informative tool for evaluation of possible clinical response is “immunoscore”
(IS)–the combination of CD3+ and CD8+ T-cell densities in the tumor core and its inva-
sive margin [101]. The IS is the first biomarker recommended by academic institutions
quantifying the tumor immune infiltrate for a prognostic purpose (the ESMO guidelines
2020 and the 5th edition of WHO Digestive System Tumors) [107]. Further studies have
proved that biopsies-adapted IS (ISB) is an even more promising prognostic tool. ISB is
a derivation of the IS performed in initial diagnostic biopsies before nCRT that has the
advantage of evaluating the effect of the initial immune infiltrate (CD3+ and CD8+ T cells
in the tumor) on response to nCRT and clinical outcome. Additionally, as nCRT induces
histological and architectural changes, post-nCRT surgical specimen can not be assessed
by the classical IS. ISB was assessed in a multicentric cohort of 249 patients with LARC
treated with nCRT followed by radical surgery. The ISB levels correlated with the degree of
histologic response to nCRT according to:
1. the Dworak classification,
2. the ypTNM staging, i.e., the post-surgical pathologic examination,
3. the NAR score (Valentini V et al. in 2011 developed a nomogram for predicting local
recurrence, distant metastases, and OS for patients with LARC. The nomogram for OS
takes into consideration patient age, gender, the clinical tumor (cT) stage, pathologic
tumor (pT) stage, pathologic nodal (pN) stage, the dose of radiotherapy, adjuvant
chemotherapy administration and surgery type–abdominoperineal resection vs. low
anterior resection) [107–109].
Patients with ISB high were not found in the Dworak 0 non-responder group (no
histologic response to nCRT) and most of the patients with ISB low (80–90%) did not
respond well to nCRT (no downstaging, Dworak 0, 1, or 2, or NAR low, or intermediate
categories). ISB combined with post-NAT imaging increased the accuracy of histologic
good responders (ypTNM 0-I) prediction [107]. At the moment ISB has several aspects of
prognostic usefulness: it provides a strong and independent prognostic factor for DFS of
patients with rectal cancer; it predicts the response to nCRT; ISB combined with imaging
post-nCRT discriminates the group of patients with a pCR to nCRT that should benefit
from less invasive therapeutic strategies [108]. The clinical usefulness of the composite
biomarker (imaging + ISB) was tested within a cohort of “W&W” patients (n = 73) with post-
nCRT cCR (ycTNM 0). There was no evidence of relapse during the follow-up period in
patients with ISB high. These results suggest that ISB could be a novel biomarker that might
be used in the clinic for a better selection of patients eligible for the “W&W” strategy [107].
7.3. Tissue-Based Tumor Molecular Biomarkers
Although several molecular biomarkers in tumor tissues have been proposed as
predictive of response to nCRT, they still are not used on an everyday basis.
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Tumors that macroscopically look-alike can express a wide range of different muta-
tions. There is intra-tumoral heterogeneity, which illustrates the danger of predicting pCR
and supporting a non-operative management strategy that is based only on biopsy sample
results. The Sao Paulo group in 2017 found that 60% of the mutations were present in only
one fragment and only 27% of mutations were expressed in all fragments. The coexistence
of cancer cell subpopulations within a single rectal cancer with distinct morphological
features and genetic mutations makes the samples of single-biopsy not representative of
the entire primary tumor. Unfortunately, a biopsy sample from one area of the primary
tumor may contain cancer cells that are resistant to nCRT, while biopsy taken from another
area—cells that are sensitive to nCRT [110].
Although there are some imperfections, molecular markers have the greatest future
potential in the prediction of clinical response [111].
7.3.1. DNA Mutation and DNA Methylation
KRAS, NRAS, and BRAF status are examples of attempts to predict pCR at a molecular
level. KRAS mutation only and KRAS/TP53 mutation combination were found to be
associated with a lower pCR rate in patients with LARC after nCRT in retrospective
studies [12].
Duldulao et al. in 2013 carried out TP53 and KRAS genotyping in rectal cancer and
presented that tumors with the KRAS mutation had a lower possibility to achieve pCR
than those with wild-type KRAS. In their research, tumors with KRAS codon 13 mutations
didn’t achieve pCR and also had a higher incidence of the TP53 mutation compared with
tumors with other KRAS mutations. These results suggested that mutations in different
KRAS codons may have different effects on the resistance of rectal cancer to nCRT and that
the rectal cancers carrying TP53 and KRAS mutations have a lower opportunity to respond
to nCRT compared with wild-type tumors [83,112].
Several researches have investigated the association of DNA methylation with re-
sponse to nCRT and prognosis in LARC. While most investigations examined DNA methy-
lation in a limited number of genes, Gaedcke et al. in 2014 profiled whole-genome methyla-
tion in 11 rectal cancer patients prior to nCRT using CpG island array analyses. Although
the association of DNA methylation and response to nCRT was not evaluated in the
study, the DNA methylation status of these regions was significantly associated with
DFS [105,113].
7.3.2. Gene Expression Profiles
Gene expression profiling of tumor tissues has the potential to identify gene signatures
related to response to nCRT. Agosini et al. in 2015 examined gene expression profiles of
pre-treatment biopsies. A set of 19 genes was significantly variously expressed between
responders and non-responders. The resultant logistic regression model consisting of
X-ray repair cross-complementing protein 3 (XRCC3), zinc Finger Protein 160 (ZNF160),
additional sex combs-like protein 2 (ASXL2) and ATP dependent DNA helicase homolog
(HFM1) successfully distinguished responders and non-responders with an accuracy of
95% [105,114]. The same group also identified seven genes (aldo-keto reductase family
1 member C3 (AKR1C3), C-X-C motif chemokine ligand 9 (CXCL9), CXCL10, CXCL11,
matrix metalloproteinase-12 (MMP12), indoleamine 2,3-dioxygenase 1 (IDO1), and HLA
class II histocompatibility antigen, DR α chain (HLA-DRA)) in immune system pathways,
that can distinguish responders from non-responders [105,115].
Neuronal pentraxin II (NPTX2) has been also verified using quantitative real-time
polymerase chain reaction in an independent set of tumor specimens from rectal cancer
patients, and it has been found that decreased NPTX2 gene expression levels are associated
with improved response to nCRT and prognosis [105,116].
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7.3.3. MicroRNA (miRNA)
Differential miRNA expression has also been associated with response to NAT. Several
studies have revealed multiple miRNA’s that are upregulated or downregulated in rectal
cancer if compared with normal mucosa, however, only part of them have the predictive
potential for the response to NAT (Table 4) [2,12,14,105,117–130].
A review by De Palma et al. in 2020, who was assessing 61 articles, identified a total of
77 miRNAs that are holding a predictive value, however, only six miRNAs (let-7f, miR-21,
miR-145, miR-622, miR-630, and miR-1183) exhibited significant differences in two or more
independent studies [14].
Table 4. MicroRNA in rectal cancer associated with response to NAT.
Upregulated miRNA Downregulated miRNA
miR-137 miR-143 miR-923 miR-720
miR-125 miR-194 miR-486-5p miR-215
miR-1183 miR-866-3p miR-34b miR-190b
miR-483-5p miR-379 miR-1274b miR-29b-2
miR-125a-3p miR-154 miR-450a miR-590-5p
miR-1224-5p miR-1542-5p miR-450b-5p miR-153
miR-622 miR-363 miR-99a miR-519c-3p
miR-196b miR-1290 miR-519b-3p miR-561
miR-223 miR-188-5p miR-1233 miR-30b
miR-494 miR-1471 miR-650 miR-145
miR-513a-5p miR-1909 miR-1243 miR-148a
miR-513b miR-21-5p miR-125b miR-375
miR-31 miR-671-5p miR-345 miR-519b






7.4. Blood-Based Tumor Molecular Biomarkers
7.4.1. Protein and Metabolites
Probst et al. in 2016 has investigated the relationship between pre-nCRT CEA levels
and response to nCRT and OS in 18 113 LARC patients from a total number of 136,840 rectal
cancer patients (data of National Cancer Data Base from 2006–2011). 47% of the patients had
increased CEA levels before nCRT. Increased pre-nCRT CEA was independently associated
with decreased pCR, reduced tumor downstaging, reduced pathological tumor regression
and OS [2,105,131]. The association between elevated CEA levels and decreased response
to nCRT has been reported in several studies and it has been found that elevated CEA
level before CRT is associated with a decreased pCR rate and a low post-CRT CEA level
<0.5 ng/dL is a significant predictor of a CR and improved OS and DFS, regardless of initial
CEA levels [2,12,85,97,98,132].
Zhang et al. in 2015 assessed pre-treatment serum level of CEA and carbohydrate
antigen 19-9 (CA19-9) in 303 LARC patients who received nCRT. While serum CEA levels
were not significantly different in this study, increased serum CA19-9 levels were markedly
correlated with poor OS, DFS and distant metastasis-free survival [105,133].
Other serum biomarkers—fibrinogen, carbonic anhydrase 9 (CAIX)–elevated levels
before nCRT were found to be significant predictive factors for primary tumor regression,
downstaging and pCR [105].
7.4.2. MicroRNA (miRNA)
Measurements of the circulating miRNAs have been performed as an alternative to
the biopsy-based tissue analysis. miRNAs are promising non-invasive biomarkers due to
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their presence in a variety of body fluids (found in plasma, breast milk, tears, bronchial
lavage, amniotic, seminal, cerebrospinal, peritoneal and pleural fluids), their stability,
simple detection and disease-specific expression in human tissues [14,134].
Currently, only a few studies have explored the potential of circulating miRNAs as
predictive biomarkers in LARC patients [14].
D’Angelo et al. in 2016 performed miRNA microarrays analysis on biopsy speci-
men gathered before nCRT with a following evaluation of serum. Among eleven miR-
NAs which differed significantly between responders and non-responders (decreased in
non-responders: miR-200a, miR-378, miR-33a, miR-338-3p, miR-30e; increased in non-
responders: miR-299-5p, miR-125b, miR-409-3p, miR-127-3p, miR-154, miR-214), levels of
miR-125b were additionally examined in serum from 34 LARC patients. It was found that
serum miR-125b levels were notably higher in non-responders than responders [105,135].
Another study by Yu J et al. in 2016 reported that low miR-345 levels extracted from the
serum of LARC responder patients (TRG 1–2) were associated with nCRT sensitivity when
compared to non-responders. Similarly in a study by Hiyoshi Y et al. in 2017, low serum
levels of miR-143 were associated with pathological response to nCRT in 94 patients [14].
Overall, currently known circulating miRNAs associated with response to NAT in
LARC are: miR18b, miR-20a, miR-125b-1, miR-1183, miR-130a, miR-199b-5p, miR-301a-3p
(high expression); miR-125b, miR-143, miR-100-5p, miR-345, miR-21-5p, miR-1246, miR-
1229-5p, miR-96-5p (low expression). Although circulating miRNAs may reflect the tumor
status, at the moment, this relationship has to be further investigated [14].
7.4.3. Circulating Tumor Cells (CTCs)
Circulating tumor cells (CTC) may also present tumor response. Sun et al. identified
CTCs by using epithelial cell-adhesion molecule (EpCAM) magnetic bead-based enrich-
ment combined with a cytometric approach. A notable difference was detected in the
levels of post-CRT CTCs and ∆%CTC (i.e., the percentage difference in CTC levels between
pre-nCRT and post-nCRT) between responders and non-responders [105,136].
Magni et al. identified CTCs by using the CellSearch System in peripheral blood drawn
before and after nCRT. Reduced amount of CTCs after nCRT were detected in the blood
samples of responders, while no significant changes were noticed in the non-responder
group [105,137].
7.4.4. Circulating Cell-Free Nucleic Acids
Circulating cell-free nucleic acids (i.e., circulating DNA (ctDNA) or circulating RNA
(ctRNA)), arising from primary and metastatic lesions, as well as CTCs, can be a potential
material for liquid biopsy in rectal cancer patients. Sun et al. examined O6-methylguanine-
DNA methyltransferase (MGMT) promoter methylation and KRAS mutation in plasma
cell-free DNA (cfDNA) and detected that post-CRT cell-free DNA levels were found to be
significantly lower in patients with response to CRT than in non-responders [138].
7.4.5. Host Immune Response
Cytokines like interleukin (IL)-6 and IL-8 have been related with response to nCRT
in rectal cancer [105,139]. Tada et al. in 2013 evaluated the concentration of monocyte
chemoattractant protein-1 (MCP-1), interferon-gamma (IFN-γ), tumor necrosis factor-α
(TNF-α), IL-2, IL-4, IL-6, IL-10, C-C motif chemokine ligand-5 (CCL-5), soluble CD40-ligand
and TNF-related apoptosis-inducing ligand (TRAIL). While no significant association of
cytokine levels with response to nCRT was observed before nCRT, levels of TNF-α and IL-6
after nCRT were significantly higher in non-responders compared to responders, also a
significant reducement of CCL-5 and soluble CD40-ligand was detected in the responder
group after nCRT [2,105,140].
Several researches have assessed the association of neutrophil-to-lymphocyte ratio
(NLR) with response to nCRT [83,105,138]. Caputo et al. in 2016 assessed NLR and derived
neutrophil-to-lymphocyte ratio (d-NLR) before and after nCRT in rectal cancer patients.
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Higher NLR and d-NLR after nCRT was significantly associated with poor response to
nCRT and postoperative complications [105,141].
A high modified Glasgow prognostic score (mGPS; a combination of C-reactive protein
and albumin levels), low lymphocyte-to-monocyte ratio and low platelet-to-lymphocyte
ratio have been associated with a poor response to CRT as well [83].
8. Concluding Remarks
To this date, the accuracy of prediction and identification of pCR, using clinical,
histological, endoscopic and radiological assessments, is not sufficient. Prediction of CR is
complex, mainly due to the heterogeneity of patient and tumor factors, different treatment
regimens (type, duration of chemoradiation, interval to the surgery) and assessment of
treatment response. The difficulties of accurate identification of CR are related to the
mismatch of the cCR and pCR in a particular proportion of the cases. The disconcordance
of the pCR and cCR seems to be related to the sensitivity of the examinations that are used
for setting up the diagnosis of CR.
At the moment, the diagnosis of cCR is based on clinical, endoscopic, MRI findings and
the results of post-NAT biopsy and post-NAT CEA level. As it was assessed in the review,
the clinical and endoscopic findings of local status are far enough not sufficient to predict
the rate of pCR. Due to the different mechanisms of tumor mass reduction (shrinkage
or fragmentation) and the possibility of geographical miss, the post-NAT tissue biopsy
should not be considered as the affirmative examination for pCR as well. And the last–MRI
examination, although it is potentially the most precise radiological method for evaluation
of CR, can’t be assumed as the leading confirming parameter. Unfortunately, sensitivity
and specificity levels prove that even with additional improvements (DWI-MRI) and in
hands of an experienced radiologist, still there is a very high possibility for misdiagnosis.
The imperfectness of previously mentioned diagnostic tools may explain the cases of
local recurrence in patients who were diagnosed to have cCR and proposed for further
“W&W” strategy. As several studies of postoperative morphological examinations have
revealed, the numbers of “real” CR (pCR) are almost two to three times lower, therefore
the existence of accurate diagnostic tools is crucial for safe guidance of “W&W” strategy.
Implementation of new radiological approaches like PET/MRI may improve the overall
accuracy of re-staging but at this moment it is still not used on an everyday basis.
At present, there are two main courses of development that are focused on the CR: (1)
the exploration and evaluation of potentially more sensitive and specific diagnostic tools to
reach more accurate results and reduce the disconcordance of cCR and pCR rates and (2)
modification of the standard therapy approach to reach higher rates of pCR.
Multiple efforts of finding the clinical markers that would bring the pre- and post-NAT
assessment to the closest point of LARC behaviour prediction are focused on winning
the chance to avoid standard treatment approach in a particular population that would
benefit from organ-preserving or non-surgical strategy with the same results of oncological
safety and optimal prognosis. At present, such predictive markers are covering a wide area
of sources, including clinical, morphological, genetical and molecular levels. Although
several molecular biomarkers have been offered as potential predictors of response to
nCRT, none of these has reached the regular clinical application yet.
Several programmed prognostic models have been offered to optimise the clinical
evaluation and to increase the accuracy of pCR prediction. To this date, the performance
of an artificial neural network (ANN) model evaluated by Huang et al. in 2020 in pCR
prediction in patients with LARC has proved itself as the most accurate (if compared with
k-nearest neighbour (KNN), support vector machine (SVM), naïve Bayes classifier (NBC)
and multiple logistic regression (MLR) models) [98].
Another direction of the studies regarding CR is the optimisation and modification of
current NAT to increase the numbers of pCR and long-term prognosis in LARC patients.
At the moment, the standard NAT of LARC includes EBRT with or without concurrent
ChT. Several studies reveal that increase of radiation doses, the addition of ChT agents
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are potentially promising for better tumor response and higher pCR rates. For example,
the last update on NAT optimisation was revealed in the American Society of Clinical
Oncology (ASCO) 2020 virtual scientific meeting where the results of clinical trials OPRA,
RAPIDO and PRODIGE 23 were presented, establishing total neoadjuvant therapy as a
new standard of care for LARC with promising short-term and long-term results [142].
However, in the unyielding way of finding the most effective therapy combinations, we
shouldn’t forget the general principle–what is harmful to the tumor, most likely is harmful
to the host as well. The risks of potential toxicity and NAT-related complications have to be
carefully weighted before implementation in clinical practice to provide the most optimal
treatment option to the patient and to avoid breaking the border of risks and benefits.
Another modality of the therapy modification involves the shifting of the surgical
intervention after NAT with a tendency of careful delay. The most appropriate time
window between the ending of the NAT and surgery is another aspect with not entirely
clear defined boundaries. Studies suggest that the longer is the observational period, the
higher the possibility of reaching pCR, but again–this strategy demands careful evaluation,
risk and benefit weighting and strict patient cooperation.
In conclusion, the overall benefit in the determination of CR after NAT is the opportu-
nity to guide more personalized treatment strategies. In clinical practice the presence of
cCR demands more careful diagnostic approach, strict follow-up strategy, considering a cer-
tain risk of local recurrence or dissemination, but in the majority of the cases–is associated
with relevantly higher patient overall life quality. Accordingly, there has been a growing
interest in alternative approaches with less morbidity, including the organ-preserving “W
and W” strategy, in which surgery is omitted in patients who have achieved a cCR. On the
other hand, although surgical resection demands reconciliation with possible postoperative
complications or permanent dysfunctions and is related with significant morbidity and
decreased quality of life, the presence of postoperative pCR is associated with the most
stable and stress-less oncologic outcome for the patient and medical professional.
The perseverance of clinical researches and implementation of new diagnostic tools
and therapeutical algorithms hopefully will lead to the optimal, individualized and patient-
friendly treatment solutions in a care of LARC patients.
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